14-3-3 eta/YWHAH Antibody [H13P22]

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:1000 IP1:20 FCM1:100

Application
WB, IP

Reactivity
Mouse, Rat, Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
28 kDa 28 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
14-3-3 eta/YWHAH Antibody [H13P22] detects endogenous levels of total 14-3-3 eta/YWHAH protein.

Clone
H13P22

Synonym(s)
YWHA1, YWHAH, 14-3-3 protein eta, Protein AS1

Background
14-3-3 eta (YWHAH) is a member of the conserved 14-3-3 adaptor family that forms phospho‑serine/phospho‑threonine–dependent dimers and functions as a soluble scaffold integrating multiple signaling pathways that control cell survival, metabolism, and stress responses, with particularly high expression in the nervous system and clear involvement in immune-mediated pathology. The protein adopts the typical 14-3-3 architecture of an antiparallel dimer built from α‑helical monomers, each containing a conserved amphipathic groove that recognizes RSXpSXP and related phosphopeptide motifs; binding of a phosphorylated client along this groove can mask functional sites, stabilize specific conformations, prevent dephosphorylation, or alter subcellular localization, thereby tuning activity and turnover of diverse kinases, transcription factors, and cytoskeletal regulators. In neurons, 14-3-3 proteins including the eta isoform interact directly with tau via multiple sites, promote its phosphorylation by a panel of tau kinases, and can induce aggregation of nonphosphorylated tau while protecting phosphorylated tau from dephosphorylation, which shifts the balance between microtubule binding and aggregate formation and positions 14-3-3 as an active participant in tau oligomerization and neurofibrillary tangle–related pathology. High neuronal abundance of 14-3-3 allows it to compete with tubulin for tau binding and to modulate the steady‑state levels and aggregation propensity of both wild-type and mutant tau, implicating YWHAH and related isoforms as contributors to tauopathies and as potential modulators of tau‑targeted strategies. In the immune system and joint microenvironment, 14-3-3 eta is released into synovial fluid and circulation where exogenous 14-3-3η can stimulate macrophages, monocytes, and fibroblast‑like synoviocytes, activating JAK–STAT, PI3K–AKT–mTOR, MAPK/ERK, JNK/AP‑1, and FOXO3–SNAI1 signaling cascades and inducing production of TNFα, IL‑6, CCL2, matrix metalloproteinases, and RANKL, all of which are central mediators of inflammation, cartilage degradation, and bone erosion in rheumatoid arthritis. In rheumatoid arthritis patients show that YWHAH mRNA is markedly upregulated in peripheral blood, and serum 14-3-3η levels strongly correlate with disease activity indices, autoantibody titers, hypoxia markers such as HIF‑1α, and angiogenic factors such as VEGF; carriers of a risk YWHAH rs2858750 allele exhibit higher 14-3-3η, greater inflammatory activity, and more severe disease, indicating that this isoform links intracellular signaling, synovial hypoxia, and angiogenesis to clinically measurable joint damage.

Background

14-3-3 eta (YWHAH) is a member of the conserved 14-3-3 adaptor family that forms phospho‑serine/phospho‑threonine–dependent dimers and functions as a soluble scaffold integrating multiple signaling pathways that control cell survival, metabolism, and stress responses, with particularly high expression in the nervous system and clear involvement in immune-mediated pathology. The protein adopts the typical 14-3-3 architecture of an antiparallel dimer built from α‑helical monomers, each containing a conserved amphipathic groove that recognizes RSXpSXP and related phosphopeptide motifs; binding of a phosphorylated client along this groove can mask functional sites, stabilize specific conformations, prevent dephosphorylation, or alter subcellular localization, thereby tuning activity and turnover of diverse kinases, transcription factors, and cytoskeletal regulators. In neurons, 14-3-3 proteins including the eta isoform interact directly with tau via multiple sites, promote its phosphorylation by a panel of tau kinases, and can induce aggregation of nonphosphorylated tau while protecting phosphorylated tau from dephosphorylation, which shifts the balance between microtubule binding and aggregate formation and positions 14-3-3 as an active participant in tau oligomerization and neurofibrillary tangle–related pathology. High neuronal abundance of 14-3-3 allows it to compete with tubulin for tau binding and to modulate the steady‑state levels and aggregation propensity of both wild-type and mutant tau, implicating YWHAH and related isoforms as contributors to tauopathies and as potential modulators of tau‑targeted strategies. In the immune system and joint microenvironment, 14-3-3 eta is released into synovial fluid and circulation where exogenous 14-3-3η can stimulate macrophages, monocytes, and fibroblast‑like synoviocytes, activating JAK–STAT, PI3K–AKT–mTOR, MAPK/ERK, JNK/AP‑1, and FOXO3–SNAI1 signaling cascades and inducing production of TNFα, IL‑6, CCL2, matrix metalloproteinases, and RANKL, all of which are central mediators of inflammation, cartilage degradation, and bone erosion in rheumatoid arthritis. In rheumatoid arthritis patients show that YWHAH mRNA is markedly upregulated in peripheral blood, and serum 14-3-3η levels strongly correlate with disease activity indices, autoantibody titers, hypoxia markers such as HIF‑1α, and angiogenic factors such as VEGF; carriers of a risk YWHAH rs2858750 allele exhibit higher 14-3-3η, greater inflammatory activity, and more severe disease, indicating that this isoform links intracellular signaling, synovial hypoxia, and angiogenesis to clinically measurable joint damage.

References
https://pubmed.ncbi.nlm.nih.gov/35190930/ https://pubmed.ncbi.nlm.nih.gov/21876254/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%